The Ocular Gene Delivery Landscape
Open accessThe DOI matches its Crossref record; 79 of the 81 references it cites were found in a registry or an index; 19 of the 88 sources its claims cite were checked for support.
Abstract
The eye is at the forefront of developing therapies for genetic diseases. With the FDA approval of the first gene-therapy drug for a form of congenital blindness, numerous studies have been initiated to develop gene therapies for other forms of eye diseases. These examinations have revealed new information about the benefits as well as restrictions to using drug-delivery routes to the different parts of the eye. In this article, we will discuss a brief history of gene therapy and its importance to the eye and ocular delivery landscape that is currently being investigated, and provide insights into their advantages and disadvantages. Efficient delivery routes and vehicle are crucial for an effective, safe, and longer-lasting therapy.
Overview
CoChat Summary
TL;DR
This review surveys ocular gene delivery, comparing intravitreal, subretinal, and suprachoroidal routes and non-viral versus viral vectors for retinal gene therapy. It concludes that rAAVs are currently the safest and most reliable vehicles, while non-viral systems offer payload and immunogenicity advantages but remain untested in ocular clinical trials.
Key findings
- The retina can be accessed via three routes—intravitreal, subretinal, and suprachoroidal—with choice depending on target cell type. Subretinal injection is invasive and carries risks of retinal tears, detachments, and macular holes; intravitreal injection is safer but poorly transduces the outer retina due to the inner limiting membrane and vitreous; suprachoroidal injection is less invasive but requires specialized needles and AAV vectors struggle to traverse the choroid to reach RPE and photoreceptors.
- Over 300 genes are associated with inherited retinal degenerations (IRDs), and >3 million people in the United States have vision impairment, expected to double to ~6 million by 2050.
- Non-viral vectors include lipid-, peptide-, polymer-based nanoparticles and naked DNA. They can accommodate large plasmid DNA, are less immunogenic, carry no insertional mutagenesis risk, and have low production cost; ECO nanoparticles delivered RPE65 in Rpe65−/− mice, and CK30-PEG-compacted nanoparticles transfected RPE and photoreceptors and treated Rpe65−/− and Abca4−/− mice. However, non-viral ocular gene delivery has not yet entered clinical trials for ocular diseases.
- Viral vectors differ in packaging capacity: retrovirus 8 kb, lentivirus 8–9 kb, adenovirus 30–40 kb (about 18.5% of clinical trials use adenoviral vectors), and AAV genome 4.7 kb with therapeutic payload under 5 kb. rAAV capsid engineering—AAV8, AAV8(Y733F), AAV7m8, AAV8BP2, and AAV-PHP.eB—improves retinal tropism; Luxturna was FDA-approved in 2018. rAAV limitations include immune responses, neutralizing antibodies, and <5 kb packaging capacity.
Methods
- Narrative review; no primary experimental design, sample, or statistical analysis is reported. It synthesizes literature on gene therapy history, retinal disease genetics, ocular delivery routes, and vector classes.
- Discusses non-viral vectors (lipid-based, peptide-based, polymer-based, naked DNA) and viral vectors (retroviral, lentiviral, adenoviral, AAV), citing animal-model and clinical-trial examples.
- No systematic search strategy, inclusion criteria, or meta-analysis is described.
Limitations
- The paper does not state limitations of its own review. Evident from the text: it is a narrative review without systematic search criteria, quantitative synthesis, or formal risk-of-bias assessment.
- Field limitations stated in the paper include anatomical barriers in the retina and pH sensitivity of nanoparticles that hinder efficient non-viral delivery and prolonged gene expression; species-specific differences mean promising rodent results may not hold in larger species such as sheep, pigs, and non-human primates.
- rAAV limitations stated include intraocular inflammation, loss of efficacy, neutralizing antibodies against capsids, and limited transgene size (<5 kb), with dual AAV vector systems and nanoparticles being developed as alternatives.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
11 Valid · 3 Not valid · 53 Not checked · 16 Own results and interpretations
Every source the paper cites for this claim was checked and supports it.
In the paper
“The NPs that undergo clathrin-mediated endocytosis can end up in endosomes, which mature to endolysosomes and undergo degradation.”
§ The Ocular Gene Delivery Landscape > 2. Gene Therapy > 2.3. Vectors for Gene Delivery
What the sources say
- Supportedcites [30] Behzadi, 2017, Cellular uptake of nanoparticles: Journey inside the cell, Chem. Soc. Rev. source
Section 3.2 says particles entering through clathrin-mediated endocytosis frequently end up in degradative lysosomes. Section 6 describes endocytic cargo entering early endosomes, which can mature into late endosomes and fuse with lysosomes to form endolysosomes, where the contents encounter degradation enzymes. The claim’s “can” reflects that this is one possible fate. (LLM, conf=0.93)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources that could be checked couldn’t confirm or dispute this claim.
In the paper
“Several liposome formulations have been tested for DNA delivery to ocular tissues using intravitreal and subretinal routes [33].”
§ The Ocular Gene Delivery Landscape > 2. Gene Therapy > 2.3. Vectors for Gene Delivery
What the sources say
- Could not verifycites [33] Balazs, 2011, Liposomes for use in gene delivery, J. Drug Deliv. sourceExperimental — accuracy not yet measured
Our copy of Balazs & Godbey (2011) is a complete review organised by lipid charge (Sections 3 'Cationic Lipids', 4 'Neutral Lipids', 6 'Concluding Remarks') and discusses DOTMA/DOTAP/DC-Chol/DOSPA/DOGS formulations, DOPE helper lipids and packing phases, with in vivo/organ examples limited to mouse lung, hepatoma (Hep G2) cells, airways, peritoneal tumour and developing embryos (Sec. 3.1.1, Sec. 4.1, refs 29-30, 60-63). No passage in our copy mentions ocular or eye tissue, the retina, or intravitreal or subretinal administration (searched: intravitreal, subretinal, eye, retina, ocular administration route), so the specific point the citing sentence attributes to this source is not addressed here. Absence is not contradiction, and the paper names no alternative origin for the ocular claim. (LLM, conf=0.70)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Could not verify
Every source the paper cites for this claim was checked and supports it.
In the paper
“Liposomes-protamine-DNA (LPD), in combination with a nuclear localization signal (NLS) peptide and a transactivator of transcription (TAT) peptide, make cell-specific and efficient gene delivery with sustained gene expression [35].”
§ The Ocular Gene Delivery Landscape > 2. Gene Therapy > 2.3. Vectors for Gene Delivery
What the sources say
- Supportedcites [35] Wang, 2015, Lipid Nanoparticles for Ocular Gene Delivery, J. Funct. Biomater. source
Section 4, “Lipid-Based Nanoparticles,” directly describes an LPD nanoparticle combined with NLS and TAT peptides for efficient, cell-specific gene delivery to eye tissues with sustained expression. Section 9 clarifies that cell specificity is achieved through cell-specific promoters, rather than the peptides alone. (LLM, conf=0.95)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“Since then, AAV-mediated gene delivery into the retina has been used in several proof-of-concept studies to target photoreceptors or the RPE in mice and larger models (such as dogs) [63,64,65].”
§ The Ocular Gene Delivery Landscape > 2. Gene Therapy > 2.3. Vectors for Gene Delivery
What the sources say
- Supportedcites [63] Buck, T.M., and Wijnholds, J. (2020). Recombinant Adeno-Associated Viral Vectors (rAAV)-Vector Elements in Ocular Gene Therapy Clinical Trials and Transgene Expression and Bioactivity Assays. Int. J. Mol. Sci., 21. source
Section 5.6.2 reports rAAV delivery to photoreceptors and RPE cells in mouse retinal-disease models. The References also list AAV-mediated cone rescue in a mouse model and gene therapy rescuing photoreceptor blindness in dogs. Together, these support the broad statement that retinal AAV delivery has been used in proof-of-concept animal studies. (LLM, conf=0.86)
- Not checked yetcites [64] Acland, 2001, Gene therapy restores vision in a canine model of childhood blindness, Nature Genet. source
- Supportedcites [65] Beltran, 2012, Gene therapy rescues photoreceptor blindness in dogs and paves the way for treating human X-linked retinitis pigmentosa, Proc. Natl. Acad. Sci. USA source
This paper supports the dog-photoreceptor example among the sentence’s several citations. The Materials and Methods describe subretinal AAV2/5 gene delivery in dogs, and the Results report expression in photoreceptors and photoreceptor preservation in treated areas; this citation need not independently establish the mouse or RPE examples. (LLM, conf=0.93)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Mutations of these residues prevent the phosphorylation and subsequent ubiquitination and degradation [70].”
§ The Ocular Gene Delivery Landscape > 2. Gene Therapy > 2.3. Vectors for Gene Delivery
What the sources say
- Partly supportedcites [70] Hickey, 2017, Tropism of engineered and evolved recombinant AAV serotypes in the rd1 mouse and ex vivo primate retina, Gene Ther. sourceExperimental — accuracy not yet measured
The Introduction of Hickey et al. (2017) states that 'Mutation of surface tyrosine (Y) residues to phenylalanine (F) was found to reduce the rate of proteasome-mediated degradation and to significantly increase transgene expression in vitro and in vivo', supporting the degradation half of the claim. However, our copy nowhere mentions phosphorylation of those tyrosines or their subsequent ubiquitination, so the mechanistic chain the citing sentence attributes to this source is not in it. The paper also presents the degradation finding as someone else's result, hedged ('was found to') and credited to its reference 9 (Zhong et al., PNAS 2008), rather than as an original observation. (LLM, conf=0.75)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
36 more claims · 4 with their cited sources checked
Create a free account to see all 83 claims and to verify the 69 references still open.
- It may state two separate claims as one. 23
- Probably not a substantial claim. 23
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Similarly, lipid-based transfection systems have shown success in their ability to transfer the target genes into retinal cells in several studies, and multiple lipid-based drugs for eye diseases are already available in the clinic35,79,87–91 and for the delivery of CRISPR or ribonucleoproteins for base editing.92,93”
From Gene Therapy for Retinal Degenerative Diseases: Progress, Challenges, and Future Directions (2023) · cites this paper as [91]
Experimental — accuracy not yet measuredIn the citing paper
“The suprachoroidal injection is a recent breakthrough in the retinal gene-delivery landscape and may provide a unique opportunity to perform less invasive surgeries31,32.”
From An adeno-associated virus variant enabling efficient ocular-directed gene delivery across species (2024) · cites this paper as [31]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated major: it would touch a result — a value a result rests on, reported and recomputed p-values on opposite sides of the significance level, two passages that conflict with no sign which is right, or a cited work retracted before this paper was published.
In the paper
§ The Ocular Gene Delivery Landscape > 3. Conclusions
“the non-viral gene delivery strategy has not yet been used in any clinical trials for ocular diseases.”
§ The Ocular Gene Delivery Landscape > 2. Gene Therapy > 2.3. Vectors for Gene Delivery
“Clinical trials have been initiated for non-infectious uveitis (NIU) disease of the eye using naked DNA delivery.”
Citations
Cites
Cellular uptake of nanoparticles: Journey inside the cell
Behzadi, S., Serpooshan, V., Tao, W., Hamaly, M. A., Alkawareek, M. Y., Dreaden, E. C., Brown, D., Alkilany, A. M., Farokhzad, O. C., & Mahmoudi, M. (2017) · Chemical Society Reviews · doi:10.1039/c6cs00636a · Cited by 2,859 · cited 1×
“However, caveolinmediated endocytosis encapsulates the NPs in caveolae vesicles that enter early endosomes or endoplasmic reticulum and escape degradation [30].”
BackgroundAdeno-associated virus vector as a platform for gene therapy delivery
Wang, D., Tai, P. W. L., & Gao, G. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0012-9 · Cited by 2,444
Russell, S., Bennett, J., Wellman, J. A., Chung, D. C., Yu, Z.-F., Tillman, A., Wittes, J., Pappas, J., Elci, O., McCague, S., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31868-8 · Cited by 1,952 · cited 1×
“Notably, one of the studies involving the delivery of the RPE65 gene into mutant dogs showed therapeutic potential, which subsequently led to the approval of the first gene therapy drug (LuxturnaTM) by the Food and Drug Administration in 2018 [66].”
BackgroundT Lymphocyte-Directed Gene Therapy for ADA − SCID: Initial Trial Results After 4 Years
Blaese, R. M., Culver, K. W., Miller, A. D., Carter, C. S., Fleisher, T., Clerici, M., Shearer, G., Chang, L., Chiang, Y., Tolstoshev, P., et al. (1995) · Science · doi:10.1126/science.270.5235.475 · Cited by 1,550 · cited 1×
“French Anderson and colleagues introduced the wild-type adenosine deaminase (ADA) gene into the patient [6].”
BackgroundHildebrandt, F., Benzing, T., & Katsanis, N. (2011) · New England Journal of Medicine · doi:10.1056/nejmra1010172 · Cited by 1,331
Gene therapy restores vision in a canine model of childhood blindness
Acland, G. M., Aguirre, G. D., Ray, J., Zhang, Q., Aleman, T. S., Cideciyan, A. V., Pearce-Kelling, S. E., Anand, V., Zeng, Y., Maguire, A. M., et al. (2001) · Nature Genetics · doi:10.1038/ng0501-92 · Cited by 1,202
The renewal of photoreceptor cell outer segments
Young, R. W. (1967) · The Journal of Cell Biology · doi:10.1083/jcb.33.1.61 · Cited by 1,184 · cited 1×
“Photoreceptors, on the other hand, are predominantly endocytic [28,29].”
BackgroundEngineering adeno-associated virus vectors for gene therapy
Li, C., & Samulski, R. J. (2020) · Nature Reviews Genetics · doi:10.1038/s41576-019-0205-4 · Cited by 1,175 · cited 2×
“Some of the drugs that use retroviral gene delivery include strimvelis for SCID and Yescarta for large B cell lymphoma [48].”
BackgroundGene therapy clinical trials worldwide to 2012 – an update
Ginn, S. L., Alexander, I. E., Edelstein, M. L., Abedi, M. R., & Wixon, J. (2013) · The Journal of Gene Medicine · doi:10.1002/jgm.2698 · Cited by 1,159
Effect of genome size on AAV vector packaging
Wu, Z., Yang, H., & Colosi, P. (2010) · Molecular Therapy · doi:10.1038/mt.2009.255 · Cited by 1,029 · cited 2×
“Neutralizing antibodies against the capsid can also reduce the therapeutic potential of the gene delivery [76].”
BackgroundAdenovirus-Associated Defective Virus Particles
Atchison, R. W., Casto, B. C., & Hammon, W. M. (1965) · Science · doi:10.1126/science.149.3685.754 · Cited by 1,004
Gene therapy clinical trials worldwide to 2017: An update
Ginn, S. L., Amaya, A. K., Alexander, I. E., Edelstein, M., & Abedi, M. R. (2018) · The Journal of Gene Medicine · doi:10.1002/jgm.3015 · Cited by 903 · cited 1×
“5% of clinical trials use this vector for gene therapy [57].”
BackgroundFriedmann, T., & Roblin, R. (1972) · Science · doi:10.1126/science.175.4025.949 · Cited by 815 · cited 1×
“This study was based upon the observation that the virus contained an arginase gene [4,5].”
MethodDalkara, D., Byrne, L. C., Klimczak, R. R., Visel, M., Yin, L., Merigan, W. H., Flannery, J. G., & Schaffer, D. V. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3005708 · Cited by 734 · cited 1×
“reported the generation of a novel capsid AAV7m8, which when administered intravitreally could transduce photoreceptors in the primate fovea and the photoreceptors and RPE of mice [74].”
BackgroundPhotoreceptor degeneration: genetic and mechanistic dissection of a complex trait
Wright, A. F., Chakarova, C. F., Abd El-Aziz, M. M., & Bhattacharya, S. S. (2010) · Nature Reviews Genetics · doi:10.1038/nrg2717 · Cited by 631
Dalby, B. (2004) · Methods · doi:10.1016/j.ymeth.2003.11.023 · Cited by 619
Adenovirus vectors for gene therapy, vaccination and cancer gene therapy
Wold, W., & Toth, K. (2014) · Current Gene Therapy · doi:10.2174/1566523213666131125095046 · Cited by 555 · cited 1×
“As the transduction of the Ad activates innate immune signaling pathways and stimulates immune cells to secrete pro-inflammatory cytokines for robust adaptive immune response, these properties make the adenoviral vector useful for a vaccine vehicle [56].”
BackgroundRecent advances in the development of gene delivery systems.
Sung, Y., & Kim, S. (2019) · Biomaterials Research · doi:10.1186/s40824-019-0156-z · Cited by 458 · cited 1×
“The positively charged head binds to a negatively charged phosphate group in the DNA to form a compact structure of lipoplexes [32].”
BackgroundLiposomes for use in gene delivery
Balazs, D. A., & Godbey, W. (2011) · Journal of Drug Delivery · doi:10.1155/2011/326497 · Cited by 441 · cited 1×
“Several liposome formulations have been tested for DNA delivery to ocular tissues using intravitreal and subretinal routes [33].”
MethodNanoscopic structure of DNA condensed for gene delivery
Dunlap, D. (1997) · Nucleic Acids Research · doi:10.1093/nar/25.15.3095 · Cited by 409 · cited 1×
“In addition to phagocytosing photoreceptor outer segments in vivo, RPE can take up large naked DNA or DNA NPs by phagocytosis [26,27].”
BackgroundHigh-efficiency transduction of the mouse retina by tyrosine-mutant AAV serotype vectors
Petrs-Silva, H., Dinculescu, A., Li, Q., Min, S.-H., Chiodo, V., Pang, J.-J., Zhong, L., Zolotukhin, S., Srivastava, A., Lewin, A. S., et al. (2009) · Molecular Therapy · doi:10.1038/mt.2008.269 · Cited by 398 · cited 6×
“AAV8 is highly effective in transducing photoreceptors (PRs) and the retinal pigmented epithelium (RPE) as compared to AAV2 and AAV5 in mice [69].”
BackgroundInfluentialFinnemann, S. C., Bonilha, V. L., Marmorstein, A. D., & Rodriguez-Boulan, E. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.24.12932 · Cited by 382
Yang, Y., Jooss, K. U., Su, Q., Ertl, H. C. J., & Wilson, J. M. (1996) · PubMed · Cited by 375
Rai, R., Alwani, S., & Badea, I. (2019) · Polymers · doi:10.3390/polym11040745 · Cited by 350 · cited 1×
“Some natural polymers are chitosan, dextran, and gelatin [38].”
BackgroundSuprachoroidal drug delivery to the back of the eye using hollow microneedles
Patel, S. R., Lin, A. S. P., Edelhauser, H. F., & Prausnitz, M. R. (2011) · Pharmaceutical Research · doi:10.1007/s11095-010-0271-y · Cited by 330 · cited 2×
“This method has been successful in large-animal models and was demonstrated to be a safer approach in a phase 3 clinical trial to treat uveitis with macular edema [20,21].”
MethodLessons learned from the gene therapy trial for ornithine transcarbamylase deficiency
Wilson, J. M. (2009) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2008.12.016 · Cited by 299 · cited 1×
“Ads are an attractive delivery system because of their broader tropism, grown as high-titer recombinant viruses present in an episomal state, and their ability to transduce dividing and non-dividing cells [55].”
BackgroundProduction and clinical development of nanoparticles for gene delivery
Chen, J., Guo, Z., Tian, H., & Chen, X. (2016) · Molecular Therapy - Methods & Clinical Development · doi:10.1038/mtm.2016.23 · Cited by 274
A brief history of gene therapy
Friedmann, T. (1992) · Nature Genetics · doi:10.1038/ng1092-93 · Cited by 273 · cited 1×
“The concept of using gene transfer into host cells to treat an underlying genetic condition arose in the 1960s and was later revolutionized by recombinant DNA technology and genetic engineering [3].”
BackgroundBeltran, W. A., Cideciyan, A. V., Lewin, A. S., Iwabe, S., Khanna, H., Sumaroka, A., Chiodo, V. A., Fajardo, D. S., Román, A. J., Deng, W.-T., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1118847109 · Cited by 260
Self-citationPeriocular routes for retinal drug delivery
Raghava, S., Hammond, M., & Kompella, U. B. (2004) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.1.1.99 · Cited by 257 · cited 1×
“Suprachoroidal injections are a recent breakthrough in the retinal gene-delivery landscape [18].”
BackgroundEngineering adeno-associated viral vectors to evade innate immune and inflammatory responses
Chan, Y. K., Wang, S. K., Chu, C. J., Copland, D. A., Letizia, A. J., Costa Verdera, H., Chiang, J. J., Sethi, M., Wang, M. K., Neidermyer, W. J., et al. (2021) · Science Translational Medicine · doi:10.1126/scitranslmed.abd3438 · Cited by 215 · cited 1×
“They achieved this by incorporating immunomodulatory noncoding sequences to “cloak” the vector from immune responses [77].”
BackgroundSelf-citationEfficient Non-Viral Ocular Gene Transfer with Compacted DNA Nanoparticles
Farjo, R., Skaggs, J., Quiambao, A. B., Cooper, M. J., & Naash, M. I. (2006) · PLoS ONE · doi:10.1371/journal.pone.0000038 · Cited by 208 · cited 1×
“In addition to phagocytosing photoreceptor outer segments in vivo, RPE can take up large naked DNA or DNA NPs by phagocytosis [26,27].”
BackgroundViral vectors for gene therapy: Current state and clinical perspectives
Lukashev, A. N., & Zamyatnin, A. A. (2016) · Biochemistry (Moscow) · doi:10.1134/s0006297916070063 · Cited by 170 · cited 1×
“The main advantage of this viral vector is the persistent gene transfer in the transduced tissue and the preferential integration at the 3′ region of the host gene [49].”
BackgroundBramall, A. N., Wright, A. F., Jacobson, S. G., & McInnes, R. R. (2010) · Annual Review of Neuroscience · doi:10.1146/annurev-neuro-060909-153227 · Cited by 163
Tailoring the AAV vector capsid for gene therapy
Vandenberghe, L. H., Wilson, J. M., & Gao, G. (2009) · Gene Therapy · doi:10.1038/gt.2008.170 · Cited by 155 · cited 1×
“The therapeutic payload must be under 5 kb and must include the regulatory elements, such as the promoter and polyadenylation signal [61,62].”
BackgroundDNA nanoparticle-mediated ABCA4 delivery rescues Stargardt dystrophy in mice
Han, Z., Conley, S. M., Makkia, R. S., Cooper, M. J., & Naash, M. I. (2012) · Journal of Clinical Investigation · doi:10.1172/jci64833 · Cited by 150
The ciliopathies: a transitional model into systems biology of human genetic disease
Davis, E. E., & Katsanis, N. (2012) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2012.04.006 · Cited by 150 · cited 1×
“Retinal degeneration due to photoreceptor dysfunction is also commonly observed in autosomal recessive syndromic disorders, such as Usher Syndrome, Bardet– Biedl Syndrome, Senior-Loken Syndrome, and Joubert Syndrome [12,13].”
BackgroundEvaluation of Dose and Safety of AAV7m8 and AAV8BP2 in the Non-Human Primate Retina
Ramachandran, P. S., Lee, V., Wei, Z., Song, J. Y., Casal, G., Cronin, T., Willett, K., Huckfeldt, R., Morgan, J. I. W., Aleman, T. S., et al. (2017) · Human Gene Therapy · doi:10.1089/hum.2016.111 · Cited by 147 · cited 1×
“Recent work from the Bennett lab showed the development of a new AAV serotype AAV8BP2 by in vivo directed evolution [75].”
BackgroundAAV8-vectored suprachoroidal gene transfer produces widespread ocular transgene expression
Ding, K., Shen, J., Hafiz, Z., Hackett, S. F., Silva, R. L. E., Khan, M., Lorenc, V. E., Chen, D., Chadha, R., Zhang, M., et al. (2019) · Journal of Clinical Investigation · doi:10.1172/jci129085 · Cited by 141 · cited 2×
“This method has been successful in large-animal models and was demonstrated to be a safer approach in a phase 3 clinical trial to treat uveitis with macular edema [20,21].”
MethodFink, T. L., Klepcyk, P. J., Oette, S. M., Gedeon, C. R., Hyatt, S. L., Kowalczyk, T. H., Moen, R. C., & Cooper, M. J. (2006) · Gene Therapy · doi:10.1038/sj.gt.3302761 · Cited by 139 · cited 1×
“The nanoparticles (NPs) that are used for such delivery can accommodate large sizes of the plasmid DNA, are relatively safer and less immunogenic, maintain long-term protein expression, and carry no risk of insertional mutagenesis [23].”
BackgroundNatkunarajah, M., Trittibach, P., McIntosh, J., Duran, Y., Barker, S. E., Smith, A. J., Nathwani, A. C., & Ali, R. R. (2008) · Gene Therapy · doi:10.1038/sj.gt.3303074 · Cited by 138 · cited 1×
“AAV8 is highly effective in transducing photoreceptors (PRs) and the retinal pigmented epithelium (RPE) as compared to AAV2 and AAV5 in mice [69].”
BackgroundGene therapy and genome surgery in the retina
DiCarlo, J. E., Mahajan, V. B., & Tsang, S. H. (2018) · Journal of Clinical Investigation · doi:10.1172/jci120429 · Cited by 127 · cited 2×
“Currently, the non-pathogenic equine infectious anemia virus (EIAV) is in clinical trials to treat Usher Syndrome [50] and Stargardt disease [51,52].”
BackgroundThe evolution of early vertebrate photoreceptors
Collin, S. P., Davies, W. I. L., Hart, N. S., & Hunt, D. M. (2009) · Philosophical Transactions of the Royal Society B Biological Sciences · doi:10.1098/rstb.2009.0099 · Cited by 124 · cited 1×
“Fossil evidence has revealed that eyes appeared ~500 million years ago and became an indispensable tool for survival [1].”
BackgroundGene transfer with liposomes to the intraocular tissues by different routes of administration.
Masuda, I., Matsuo, T., Yasuda, T., & Matsuo, N. (1996) · PubMed · Cited by 115
Binley, K., Widdowson, P., Loader, J., Kelleher, M., Iqball, S., Ferrige, G., de Belin, J., Carlucci, M., Angell-Manning, D., Hurst, F., et al. (2013) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.13-11871 · Cited by 115 · cited 1×
“Currently, the non-pathogenic equine infectious anemia virus (EIAV) is in clinical trials to treat Usher Syndrome [50] and Stargardt disease [51,52].”
BackgroundFischer, M. D., McClements, M. E., Martinez-Fernandez de la Camara, C., Bellingrath, J.-S., Dauletbekov, D., Ramsden, S. C., Hickey, D. G., Barnard, A. R., & MacLaren, R. E. (2017) · Molecular Therapy · doi:10.1016/j.ymthe.2017.05.005 · Cited by 112 · cited 1×
“Additional large-animal-model proof of concept studies, including X-linked RP, are now in clinical trials [67,68].”
BackgroundAdenoviruses as gene/vaccine delivery vectors: Promises and pitfalls
Appaiahgari, M. B., & Vrati, S. (2015) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2015.993374 · Cited by 110 · cited 1×
“Adenoviral vectors: Adenoviruses (Ad) are non-enveloped, double-stranded DNA viruses with a packaging ability of 30 to 40 kb DNA [54].”
BackgroundBerns, K. I., & Adler, S. (1972) · Journal of Virology · doi:10.1128/jvi.9.2.394-396.1972 · Cited by 101 · cited 1×
“They belong to the family Parvoviridae and genus Dependovirus because they can infect only in the presence of a helper virus [59].”
BackgroundArgyros, O., Wong, S. P., Niceta, M., Waddington, S. N., Howe, S. J., Coutelle, C., Miller, A. D., & Harbottle, R. P. (2008) · Gene Therapy · doi:10.1038/gt.2008.113 · Cited by 96 · cited 1×
“The scaffold matrix attachment region (S/MAR)-containing sequence has been shown to maintain the plasmid in an episomal state and bind to nuclear scaffold proteins [44].”
BackgroundGhosh, A., Yue, Y., & Duan, D. (2011) · Human Gene Therapy · doi:10.1089/hum.2010.122 · Cited by 95
Lipid Nanoparticles for Ocular Gene Delivery
Wang, Y., Rajala, A., & Rajala, R. (2015) · Journal of Functional Biomaterials · doi:10.3390/jfb6020379 · Cited by 93 · cited 1×
“Liposomes-protamine-DNA (LPD), in combination with a nuclear localization signal (NLS) peptide and a transactivator of transcription (TAT) peptide, make cell-specific and efficient gene delivery with sustained gene expression [35].”
BackgroundBuck, T., & Wijnholds, J. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21124197 · Cited by 92
Approval of First CAR-Ts: Have we Solved all Hurdles for ATMPs?
Seimetz, D., Heller, K., & Richter, J. (2019) · Cell Medicine · doi:10.1177/2155179018822781 · Cited by 90
Emerging patent landscape for non-viral vectors used for gene therapy
Picanço-Castro, V., Pereira, C. G., Covas, D. T., Porto, G. S., Athanassiadou, A., & Figueiredo, M. L. (2020) · Nature Biotechnology · doi:10.1038/s41587-019-0402-x · Cited by 88 · cited 1×
“clinical grade plasmid pEYS606 currently in the clinical trial is electro-transferred to the ciliary muscle of the eye [42,43].”
BackgroundRogers, S., Löwenthal, A., Terheggen, H. G., & Columbo, J. P. (1973) · The Journal of Experimental Medicine · doi:10.1084/jem.137.4.1091 · Cited by 77 · cited 1×
“This study was based upon the observation that the virus contained an arginase gene [4,5].”
MethodKoirala, A., Makkia, R. S., Conley, S. M., Cooper, M. J., & Naash, M. I. (2013) · Human Molecular Genetics · doi:10.1093/hmg/ddt013 · Cited by 75 · cited 1×
“These plasmid modifications have been shown to be effective in gene delivery in Rpe65−/−, Abca4−/− and Rhodopsin−/− [41,45,46].”
Gene therapy for Stargardt disease associated with ABCA4 gene
Han, Z., Conley, S. M., & Naash, M. I. (2014) · Advances in Experimental Medicine and Biology · doi:10.1007/978-1-4614-3209-8_90 · Cited by 74 · cited 1×
“These plasmid modifications have been shown to be effective in gene delivery in Rpe65−/−, Abca4−/− and Rhodopsin−/− [41,45,46].”
Kang-Mieler, J. J., Dosmar, E., Liu, W., & Mieler, W. F. (2017) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2016.1227785 · Cited by 73 · cited 1×
“The retina can be accessed via three distinct routes: intravitreal, subretinal, and suprachoroidal (Figure 1) [14].”
BackgroundAdeno-Associated Viral Vectors as a Tool for Large Gene Delivery to the Retina
Trapani, I. (2019) · Genes · doi:10.3390/genes10040287 · Cited by 73
Hickey, D. G., Edwards, T. L., Barnard, A. R., Singh, M. S., de Silva, S. R., McClements, M. E., Flannery, J. G., Hankins, M. W., & MacLaren, R. E. (2017) · Gene Therapy · doi:10.1038/gt.2017.85 · Cited by 72 · cited 1×
“Mutations of these residues prevent the phosphorylation and subsequent ubiquitination and degradation [70].”
BackgroundThe future of retinal gene therapy: evolving from subretinal to intravitreal vector delivery
Ross, M., & Ofri, R. (2021) · Neural Regeneration Research · doi:10.4103/1673-5374.306063 · Cited by 67 · cited 2×
“The subretinal injection is an invasive surgical procedure in which the therapeutics are delivered between the photoreceptors and the RPE [15].”
BackgroundRetrovirus and lentivirus vector design and methods of cell conditioning
Cooray, S., Howe, S. J., & Thrasher, A. J. (2012) · Methods in Enzymology · doi:10.1016/b978-0-12-386509-0.00003-x · Cited by 65 · cited 1×
“They reverse transcribe their RNA into double-stranded DNA, which can integrate into the genome of the host cell [47].”
BackgroundGlycosidic enzymes enhance retinal transduction following intravitreal delivery of AAV2.
Cehajic‐Kapetanovic, J., Goff, M. L., Allen, A. E., Lucas, R. J., & Bishop, P. N. (2011) · PubMed Central · Cited by 57
Xu, Z., Yue, Y., Lai, Y., Ye, C., Qiu, J., Pintel, D. J., & Duan, D. (2004) · Human Gene Therapy · doi:10.1089/hum.2004.15.896 · Cited by 55
Genomic DNA nanoparticles rescue rhodopsin-associated retinitis pigmentosa phenotype
Han, Z., Banworth, M. J., Makkia, R., Conley, S. M., Al‐Ubaidi, M. R., Cooper, M. J., & Naash, M. I. (2015) · The FASEB Journal · doi:10.1096/fj.15-270363 · Cited by 54 · cited 1×
“These plasmid modifications have been shown to be effective in gene delivery in Rpe65−/−, Abca4−/− and Rhodopsin−/− [41,45,46].”
Non-viral therapeutic approaches to ocular diseases: An overview and future directions
Zulliger, R., Conley, S. M., & Naash, M. I. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.10.007 · Cited by 50 · cited 1×
“It induces minimal immune response and has the capability to be delivered in higher doses [37].”
BackgroundKoirala, A., Conley, S. M., Makkia, R., Liu, Z., Cooper, M. J., Sparrow, J. R., & Naash, M. I. (2013) · Journal of Controlled Release · doi:10.1016/j.jconrel.2013.08.299 · Cited by 47
Sun, D., Sahu, B., Gao, S., Schur, R. M., Vaidya, A. M., Maeda, A., Palczewski, K., & Lu, Z.-R. (2017) · Molecular Therapy - Nucleic Acids · doi:10.1016/j.omtn.2017.02.005 · Cited by 47 · cited 1×
“showed that ECO can efficiently deliver the RPE65 gene into the retinal pigmented epithelium in the Leber congenital amaurosis (LCA) model of Rpe65−/− mice to restore vision [36].”
BackgroundSelf-citationHollyfield, J. G., Varner, H. H., Rayborn, M. E., Liou, G. I., & Bridges, C. D. (1985) · The Journal of cell biology · doi:10.1083/jcb.100.5.1676 · Cited by 45 · cited 1×
“Photoreceptors, on the other hand, are predominantly endocytic [28,29].”
BackgroundFocused Update on AAV-Based Gene Therapy Clinical Trials for Inherited Retinal Degeneration
Fuller-Carter, P. I., Basiri, H., Harvey, A. R., & Carvalho, L. S. (2020) · BioDrugs · doi:10.1007/s40259-020-00453-8 · Cited by 41 · cited 1×
“Additional large-animal-model proof of concept studies, including X-linked RP, are now in clinical trials [67,68].”
BackgroundEngineered Capsids for Efficient Gene Delivery to the Retina and Cornea
Frederick, A., Sullivan, J., Liu, L., Adamowicz, M., Lukason, M., Raymer, J., Luo, Z., Jin, X., Rao, K. N., & O'Riordan, C. (2020) · Human Gene Therapy · doi:10.1089/hum.2020.070 · Cited by 35 · cited 1×
“Using a rational design approach, novel variants of AAV2 and AAV5 have been generated, which demonstrate improved retinal transduction in non-human primate retina and tissue [72].”
Eight Years after Jesse's Death, Are Human Research Subjects Any Safer?
Gelsinger, P., & Shamoo, A. E. (2008) · The Hastings Center Report · doi:10.1353/hcr.2008.0022 · Cited by 32 · cited 1×
“The field suffered a setback when a patient died because of gene therapy for ornithine transcarbamylase deficiency due to a massive immune response [7].”
BackgroundTouchard, E., Benard, R., Bigot, K., Laffitte, J.-D., Buggage, R., Bordet, T., & Behar-Cohen, F. (2018) · Journal of Controlled Release · doi:10.1016/j.jconrel.2018.07.013 · Cited by 32 · cited 1×
“clinical grade plasmid pEYS606 currently in the clinical trial is electro-transferred to the ciliary muscle of the eye [42,43].”
BackgroundThe genetics of retinopathy of prematurity: A model for neovascular retinal disease
Swan, R., Kim, S. J., Campbell, J. P., Chan, R. V. P., Sonmez, K., Taylor, K. D., Li, X., Chen, Y.-D. I., Rotter, J. I., Simmons, C., et al. (2018) · Ophthalmology Retina · doi:10.1016/j.oret.2018.01.016 · Cited by 30 · cited 2×
“i l i j i i i l li l re less invasive than subretinal injection and involve accessing th retina by inject g into the space between t e chor id (overlaying the RPE) and th sclera [19].”
BackgroundLong-term follow-up of a family with dominant X-linked retinitis pigmentosa
Wu, D. M., Khanna, H., Atmaca-Sonmez, P., Sieving, P. A., Branham, K., Othman, M., Swaroop, A., Daiger, S. P., & Heckenlively, J. R. (2010) · Eye · doi:10.1038/eye.2009.270 · Cited by 28 · cited 1×
“Additional disadvantages include the limited size of the transgene (<5 kb) that can be packaged into AAV capsids [78].”
BackgroundSelf-citationMannose-sensitive HRP endocytosis by the retinal pigment epithelium
Heth, C. A., & Bernstein, M. H. (1991) · Experimental Eye Research · doi:10.1016/0014-4835(91)90130-7 · Cited by 18 · cited 1×
“In the eye, the RPE shows both phagocytic and endocytic capacities [24,25].”
BackgroundRoss, M., Obolensky, A., Averbukh, E., Ezra-Elia, R., Yamin, E., Honig, H., Dvir, H., Rosov, A., Hauswirth, W. W., Gootwine, E., et al. (2020) · Human Gene Therapy · doi:10.1089/hum.2020.023 · Cited by 16 · cited 1×
“As discussed later in this article, such limitations are being worked on by modifying the delivery vehicle [16] or by using agents to temporarily disrupt the barrier for efficient transduction of the outer retina [17].”
Systemic Delivery of Genes to Retina Using Adeno-Associated Viruses
Simpson, C. P., Bolch, S. N., Zhu, P., Weidert, F., Dinculescu, A., & Lobanova, E. S. (2019) · Advances in Experimental Medicine and Biology · doi:10.1007/978-3-030-27378-1_18 · Cited by 11 · cited 1×
“eB) have been designed that can cross the blood-retinal barrier when delivered systemically [73].”
BackgroundChildhood-onset genetic cone-rod photoreceptor diseases and underlying pathobiology
Garafalo, A. V., Sheplock, R., Sumaroka, A., Román, A. J., Cideciyan, A. V., & Jacobson, S. G. (2021) · EBioMedicine · doi:10.1016/j.ebiom.2020.103200 · Cited by 10
Research works printed but not linked: 2
- Kandel, E.R. (2013). Principles of Neural Science, McGraw-Hill. [5th ed.].
- Audo, 2015, Early findings in a phase I/IIa clinical program for stargardt disease (STGD1, MIM # 248200), Invest. Ophthalmol. Vis. Sci., 56, 3819
Cited by
Gene Therapy for Retinal Degenerative Diseases: Progress, Challenges, and Future Directions
Drag, S., Dotiwala, F., & Upadhyay, A. K. (2023) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.64.7.39 · Cited by 145
Overview of Recent Advances in Nano-Based Ocular Drug Delivery
Liu, L.-C., Chen, Y., & Lu, D. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms242015352 · Cited by 172
“In such scenarios, light activation serves as a means to initiate the release of drugs within these cells and facilitate delivery into the cytoplasm [182].”
BackgroundNano-based eye drop: Topical and noninvasive therapy for ocular diseases
Wang, C., & Pang, Y. (2023) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2023.114721 · Cited by 114
An adeno-associated virus variant enabling efficient ocular-directed gene delivery across species
Luo, S., Jiang, H., Li, Q., Qin, Y., Yang, S., Li, J., Xu, L., Gou, Y., Zhang, Y., Liu, F., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-48221-4 · Cited by 39
Supe, S., Upadhya, A., Tripathi, S. D., Dighe, V. D., & Singh, K. (2023) · Drug Delivery and Translational Research · doi:10.1007/s13346-022-01281-9 · Cited by 34
Metadata
- Authors
- Sahu, B., Chug, I., & Khanna, H.
- Affiliations
- University of Massachusetts Chan Medical School (US)
- Corresponding author
- Khanna, Hemant
- ORCID
- Khanna, Hemant
- Venue
- Biomolecules
- Publisher
- MDPI AG
- Published
- 2021-08-01
- Volume
- 11
- Issue
- 8
- Pages
- 1135
- ISSN
- 2218-273X (ISSN-L)
- PMC
- PMC8394578
- OpenAlex
- W3191982495
- Cited by
- 28
- References
- 81
- Citations by year
- 2026: 3 · 2025: 5 · 2024: 9 · 2023: 7 · 2022: 2 · 2021: 2
- FWCI
- 0.46
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Biomolecules (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- The Journal of the American Medical Association (JAMA) Network (American Medical Association) (submittedVersion, cc-by)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- National Eye Institute (EY022372)
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmaceutical Science › Advanced Drug Delivery Systems
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Health Sciences › Medicine › Ophthalmology › Retinal Development and Disorders
- Keywords
- ocular gene therapy, ocular drug delivery, eye diseases, congenital blindness, history of gene therapy
- MeSH terms
- Choroidal Effusions, Animals, DNA, Eye, Eye Diseases, Genetic Vectors, Humans, Liposomes, Peptides, Viruses, Vitreous Body, Genetic Therapy, Gene Transfer Techniques, Nanoparticles, Intravitreal Injections, Subretinal Fluid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-04, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-04 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol and qwen3.8-omni-flash).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.

